HUTCHMED in US$608 million Divestment of Non-Core Joint Venture

 — HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally —

— Divestment proceeds to advance HUTCHMED’s pipeline and core innovative medicines business —

— Focused R&D investment includes HUTCHMED’s proprietary antibody-targeted therapy conjugate platform, with first candidates expected to enter clinical trials in the second half of 2025 —

https://www.globenewswire.com/news-release/2025/01/01/3003243/0/en/HUTCHMED-Announces-US-608-million-Divestment-of-Non-Core-Joint-Venture.html